Electric pulses zapping liver tumors: new hope for colorectal cancer patients?
NCT ID NCT07191548
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a procedure called irreversible electroporation (IRE), also known as Nanoknife, to treat liver tumors that have spread from colorectal cancer. IRE uses short electrical pulses to destroy cancer cells while sparing nearby blood vessels and bile ducts. The trial will enroll 50 adults who have already had chemotherapy and will measure how many tumors are completely gone after 6 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Irreversible electroporation (Nanoknife) - a procedure using electrical pulses to destroy cancer cells
- What this could lead to
- If successful, this could offer a new, targeted way to treat liver metastases from colorectal cancer without damaging nearby healthy tissue.
- What could go wrong
- This is an early-stage study with only 50 participants, so results may not apply to everyone. The procedure carries risks like bleeding or infection, and it may not fully eradicate all tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 18 years and over, able to provide informed consent and with histological confirmation of a diagnosis of colorectal cancer from primary tumour. * Liver lesions demonstrating radiological characteristics (on magnetic resonance scan) of colorectal hepatic metastases without requirement for biopsy. In the setting of an intact liver, patients with up to four metastases ≤ 4cm in size are eligible for inclusion. In the setting of proposed resection plus ablation, up to two metastases ≤ 4cm in size. In the setting of recurrence after prior hepatectomy up to two metastases ≤ 4cm in size. * Eastern Co-operative Oncology Group (ECOG) Score ≤ 2. * Rockwood Frailty Score ≤ 3. * Serum bilirubin \< 30 µmol/L. * Serum creatinine \< 150 µmol/L. * Up to two lung metastases (\< 2cm in size permitted at enrolment). * Prior treatment with at least one course of systemic chemotherapy (± biologic agent) mandated. Chemotherapy protocol is not specified and is at clinician discretion. * Primary rectal tumour can remain in situ treated with radiotherapy/chemoradiotherapy according to tumour board recommendations. Primary colonic tumour can remain in situ. * No prior hepatic tumour ablation Exclusion Criteria: * Patients involved in other research studies. * Inability to give informed consent. * Patients who are pregnant. * Accepted exclusions to IRE from consensus criteria including: * Platelet count \< 50x109 U/L. * International normalised ratio (INR) for blood clotting \> 1.7. * Prior hepatic tumour ablation. Cardiovascular fitness related exclusions: * History of ventricular arrhythmia. * Implanted pacemaker or defibrillator. * Congestive cardiac failure NYHA Class ≥ 3. Tumour-related exclusions: * Tumour ≥ 4 cm in size. * Advanced multi-site metastatic cancer (any of the following): peritoneal metastases (M1c), bone metastases, \> 2 lung metastases, all segment involvement multiple liver metastases. * Jaundice (serum bilirubin \> 30 µmol/L). * MDT/tumour recommends use of thermal ablation instead of IRE for any given lesion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma metastatic in the liver are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Manchester Royal Infirmiary
Manchester, M13 9WL, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new radiation machine cut breath holds for cancer patients?
- Immunotherapy combo aims to turn inoperable liver tumors into operable ones
- Can a custom vaccine train the body to fight liver cancer?
- AI may foresee lung complications after liver surgery
- Can targeted liver chemo turn inoperable tumors into operable ones?
- Exercise as medicine: tailored workouts may rebuild strength after cancer